Your browser is no longer supported. Please, upgrade your browser.
OREX Orexigen Therapeutics, Inc. daily Stock Chart
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own0.10% Shs Outstand151.90M Perf Week-5.43%
Market Cap66.08M Forward P/E- EPS next Y-0.31 Insider Trans0.00% Shs Float144.63M Perf Month-22.32%
Income-68.70M PEG- EPS next Q-0.16 Inst Own90.90% Short Float15.95% Perf Quarter-75.70%
Sales24.50M P/S2.70 EPS this Y-65.10% Inst Trans21.12% Short Ratio9.67 Perf Half Y-86.90%
Book/sh0.23 P/B1.89 EPS next Y39.20% ROA-31.20% Target Price1.60 Perf Year-93.42%
Cash/sh1.41 P/C0.31 EPS next 5Y- ROE-313.50% 52W Range0.39 - 6.96 Perf YTD-74.71%
Dividend- P/FCF- EPS past 5Y13.70% ROI- 52W High-93.75% Beta2.23
Dividend %- Quick Ratio6.90 Sales past 5Y81.80% Gross Margin- 52W Low11.54% ATR0.04
Employees67 Current Ratio7.30 Sales Q/Q-78.70% Oper. Margin- RSI (14)34.68 Volatility9.88% 9.56%
OptionableYes Debt/Eq2.64 EPS Q/Q- Profit Margin- Rel Volume1.15 Prev Close0.46
ShortableYes LT Debt/Eq2.64 EarningsMay 04 AMC Payout- Avg Volume2.39M Price0.44
Recom3.10 SMA20-8.81% SMA50-30.27% SMA200-78.57% Volume2,749,676 Change-5.43%
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $1 → $0.60
Mar-16-16Downgrade Piper Jaffray Overweight → Neutral
Mar-16-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $5 → $1
Feb-29-16Downgrade JP Morgan Overweight → Neutral
Feb-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-11-15Resumed BofA/Merrill Underperform
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Nov-06-15Reiterated RBC Capital Mkts Outperform $9 → $5
Oct-06-15Reiterated Piper Jaffray Overweight $21 → $11
Mar-27-15Reiterated RBC Capital Mkts Outperform $10 → $14
Jan-23-15Initiated RBC Capital Mkts Outperform $10
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
May-04-16 05:02PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online -5.43%
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:51PM  Orexigen reports 1Q loss AP
04:01PM  Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016 PR Newswire
07:07AM  Q1 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close CCBN
May-03-16 05:30PM  Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference PR Newswire
08:30AM  Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development PR Newswire
May-02-16 08:30AM  Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients PR Newswire
Apr-28-16 09:00AM  Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the World Obesity Federation PR Newswire
Apr-25-16 12:44PM  Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25 Accesswire +6.82%
09:00AM  Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees PR Newswire
Apr-21-16 09:30AM  The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen Zacks
Apr-20-16 05:00PM  Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on May 4, 2016 PR Newswire
Apr-17-16 10:04AM  How Much Potential Does Saxenda Hold for Novo?
Apr-15-16 04:17PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Apr-08-16 04:59PM  ETFs with exposure to Orexigen Therapeutics, Inc. : April 8, 2016
Apr-04-16 04:12PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events
Mar-29-16 10:50AM  ETFs with exposure to Orexigen Therapeutics, Inc. : March 29, 2016 +13.46%
Mar-28-16 11:47AM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2015 By the Numbers -5.45%
Mar-26-16 03:52PM  Five Penny Stocks To Buy Based on Smart Money Sentiment at Insider Monkey
Mar-25-16 02:01PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
Mar-22-16 01:00PM  Stocks To Watch: Market Update on Today's Stocks on the Move Accesswire
Mar-17-16 09:30AM  The Zacks Analyst Blog Highlights: GW Pharma, Orexigen, Gilead and Regeneron
Mar-16-16 04:50PM  Orexigen Buys U.S. Rights to Contrave, Inks Deal in the EU -17.19%
11:56AM  Biotech Stock Roundup: GW Pharma Soars on Epidiolex Data, Gilead's Zydelig in Trouble?
09:05AM  Top Analyst Upgrades and Downgrades: Chipotle, Oracle, Orexigen, PulteGroup, Reynolds American, Valeant and More at 24/7 Wall St.
08:06AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:20AM  Orexigen Therapeutics downgraded by JMP Securities and Piper Jaffray
Mar-15-16 04:44PM  Valeant shocks with missed 4Q results, slashed 2016 guidance -8.57%
10:47AM  Four Companies Added To Today's Stock Watchlist on Tuesday March 15, 2016 Accesswire
08:30AM  Orexigen Therapeutics Inc to Discuss Acquisition of U.S. Rights to Contrave and the Central and Eastern European Partnership with Valeant Pharmaceuticals International, Inc. Call scheduled for 8:30 am ET today
08:18AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
07:05AM  Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and Eastern Europe Distribution Agreement with Va PR Newswire
07:00AM  Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern European Countries and Turkey
07:00AM  Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine PR Newswire
07:00AM  Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United States PR Newswire
Mar-08-16 02:24PM  What Ted Cruz Gets Wrong About The FDA: Tough Regulation Can Spark Innovation at Forbes -8.86%
11:09AM  Former FDA Official Calls For Tougher Restrictions On Obesity Drug Contrave at Forbes
Mar-07-16 12:49PM  Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2015 By the Numbers +12.86%
Mar-04-16 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials
Feb-29-16 08:45AM  Top Analyst Upgrades and Downgrades: Huntington Bancshares, Nucor, Orexigen, SanDisk, Square, VIVUS and Many More at 24/7 Wall St. -26.80%
Feb-26-16 05:10PM  Edited Transcript of OREX earnings conference call or presentation 26-Feb-16 1:00pm GMT -31.21%
10:57AM  Orexigen Therapeutics (OREX) Stock Plunges on Q4 Miss at TheStreet
08:00AM  Orexigen Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:27AM  Orexigen reports 4Q loss
07:17AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:07AM  Q4 2015 Orexigen Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 PR Newswire
Feb-19-16 08:30AM  Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Full Year 2015 Financial Results on February 26, 2016 PR Newswire
Feb-18-16 05:00PM  Orexigen Therapeutics to Speak at the RBC Capital Markets 2016 Healthcare Conference PR Newswire
Feb-09-16 10:23AM  Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January at Motley Fool -7.47%
Feb-08-16 04:26PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -5.43%
Feb-04-16 08:32AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure +5.59%
Feb-02-16 04:15PM  Orexigen Therapeutics to Speak at Upcoming Investor Conferences PR Newswire
Jan-30-16 01:01PM  Biotech's Dumbest CEO Moves in 2015 at Motley Fool
Jan-25-16 01:31PM  Some cheap biotech stocks that could be buyout targets, RBC says at MarketWatch -5.73%
12:25PM  Why Zafgen Inc's Stock Is in the Red Today at Motley Fool
Jan-24-16 07:51AM  3 Stocks I Would Avoid at All Costs at Motley Fool
Jan-22-16 07:14AM  8 Stocks Under $10 Making Big Moves Higher at TheStreet
Jan-12-16 09:30AM  Orexigen Targets Profitability by 2018, Focus on Contrave
Jan-11-16 08:37AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Orexigen announces 2016 financial outlook and key priorities PR Newswire
Jan-08-16 04:17PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:15PM  Orexigen Therapeutics names Thomas Lynch as EVP, General Counsel & Secretary and Heather Ace as EVP, Global Human Resources PR Newswire
12:48PM  Blame This for Orexigen Therapeutics, Inc.'s Mind-Numbingly Bad 2015 at Motley Fool
Jan-07-16 12:04PM  Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016? at Motley Fool -6.29%
Jan-05-16 04:01PM  Orexigen Therapeutics to Speak at the J.P. Morgan 2016 Global Healthcare Conference PR Newswire
Dec-29-15 08:22AM  10 Biotechs Short Sellers Are Betting Against
Dec-28-15 01:02PM  The Worst Biotech Stocks in 2015 at Motley Fool
Dec-22-15 09:46AM  Orexigen Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-17-15 04:12PM  How Martin Shkreli Allegedly Created a Ponzi Scheme With Biotech Stocks at Fortune +7.50%
Dec-08-15 01:12PM  Orexigen Therapeutics' Stock Dropped 28% in November: Can It Recover? at Motley Fool
Dec-07-15 09:45AM  INVESTOR ALERT: 4 Stocks Under $10 With Increased Volatility Accesswire -5.94%
Dec-04-15 04:57PM  Orexigen Therapeutics, Inc.'s Stock Loses Weight on Downgrade at Motley Fool -8.60%
04:32PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial St
Dec-02-15 05:32PM  What Do Hedge Funds Think of Orexigen Therapeutics, Inc. (OREX)? at Insider Monkey
03:20PM  Zafgen Plunges On Death In Obesity-Drug Trial at Investor's Business Daily
Dec-01-15 11:06AM  Here's Why Arena Pharmaceuticals' Stock Briefly Spiked Today at Motley Fool
Nov-30-15 02:33PM  Is Model N Inc (MODN) A Good Stock To Buy? at Insider Monkey
Nov-25-15 05:35PM  Drugmakers drop weight
09:00AM  Orexigen Therapeutics to Speak at the Piper Jaffray 27th Annual Healthcare Conference PR Newswire
Nov-24-15 04:02PM  Is Marine Products Corp. (MPX) A Good Stock To Buy? at Insider Monkey
08:15AM  Direction of Market Influences - Research on Orexigen, Cara Therapeutics, Uniqure and Baozun Accesswire
Nov-18-15 01:14PM  Value Investing in BioPharma
Nov-16-15 07:45AM  Looking into the Price Movements - Research on Agenus, Straight Path, Orexigen Therapeutics and Cara Therapeutics Accesswire
Nov-11-15 07:03AM  A Competitor's Pain Proves to Be Orexigen Therapeutics' Gain in October at Motley Fool
Nov-09-15 06:29AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-06-15 04:01PM  Orexigen Therapeutics to Present at Credit Suisse 2015 Healthcare Conference PR Newswire -16.25%
02:35PM  Orexigen Q3 Loss Narrower-Than-Expected, Revenues Top
12:20PM  Why Orexigen Therapeutics, Inc.'s Stock Is Losing Weight Today at Motley Fool
Nov-05-15 10:15PM  Edited Transcript of OREX earnings conference call or presentation 5-Nov-15 10:00pm GMT
05:53PM  Orexigen reports 3Q loss
05:00PM  Orexigen Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today
04:19PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu
04:01PM  Orexigen Therapeutics Reports Financial and Business Results for the Third Quarter Ended September 30, 2015 PR Newswire
07:07AM  Q3 2015 Orexigen Therapeutics Inc Earnings Release - After Market Close
Nov-04-15 08:40AM  Technical Review of Stocks from Diverse Sectors - Research on Orexigen Therapeutics, Teligent, Tetraphase Pharmaceuticals and A10 Networks Accesswire
Nov-03-15 09:00AM  Orexigen Announces Naltrexone/Bupropion Data Presentations at ObesityWeek 2015 PR Newswire
Nov-02-15 07:04AM  3 Things You Never Knew About Medicare at Motley Fool +9.21%
Oct-30-15 12:25PM  Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today at Motley Fool
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. The company's product, Contrave also approved under the brand name of Mysimba in Europe. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.